Protagenic Therapeutics, Inc.new PTIX

OTC PTIX
$0.47 +0.00 (+0.00%)
At close: Nov 13, 2026 · 4:00 PM EST

Protagenic Therapeutics, Inc.new (PTIX) stock price is $0.47, unchanged on the day, as of Nov 13, 2026. It has a market cap of $850.80K, and is classified in the Biotechnology industry (Healthcare sector).

Key Stats
Market Cap850,797.76
P/E0.15
FCF (Yr)-2.81 Mn
ROA (Yr)73.16
EV to EBIT1.31
Net Income (Yr)1.37 Mn
Enterprise Value-3.51 Mn
Add ratio to table…

About

Protagenic Therapeutics, Inc. is a biopharmaceutical company focused on discovering and developing therapeutics for stress-related neuropsychiatric and mood disorders. The company's primary activities center on its proprietary, patent-protected lead compound, PT00114, a synthetic form of Teneurin Carboxy-terminal Associated Peptide-1 (TCAP-1). TCAP-1 is an endogenous brain signaling peptide that dampens overactive stress responses. Protagenic Therapeutics, Inc. operates…

Read more ↓
Sector: Healthcare Sector rationale The company is a biopharmaceutical firm focused on discovering and developing therapeutics such as PT00114 and PHYX-001 for neuropsychiatric and mood disorders. Its entire business model is based on the research, development, and future sale of pharmaceutical drug candidates to treat medical conditions like depression, anxiety, and epilepsy. Industries: Biotechnology Biotechnology Primary Protagenic Therapeutics is a biopharmaceutical company developing therapies derived from biological science, specifically the TCAP-1 brain signaling peptide (PT00114). The company is currently a clinical-stage developer with no product revenue, focusing on biology-based drug discovery for neuropsychiatric disorders. Pharmaceuticals Pharmaceuticals Secondary The company's Phytanix Bio Programs include the development of small-molecule and synthetic assets, such as PHYX-001 (a Kv7.2/7.3 agonist) and PHYX-005 (a stilbenoid-based asset), which align with branded pharmaceutical development. Classified using BQ-MICS CIK: 0001022899

Scenario Breakdown of Revenue (2013)

History
Peer percentiles

How Protagenic Therapeutics, Inc.new ranks

Ranked against the 695 companies in Pharmaceuticals and Biotechnology58 metrics · as of Nov 14, 2026

Valuation

12 metrics · Lower multiples rank higher; a negative multiple ranks last
  • P/EImplausibly low multiple 0.15xMedian 17.0x Not meaningful —
  • P/FCFNegative free cash flow −0.78xMedian 19.0x 18th
  • P/Operating cash flowNegative operating cash flow −0.78xMedian 16.4x 18th
  • P/SRevenue is not positive −0.67xMedian 8.38x Not meaningful —
  • P/B 0.76xMedian 2.04x 78th
  • P/Tangible bookNegative tangible equity −0.88xMedian 2.31x Not meaningful —
  • EV/EBITDANegative EBITDA −0.59xMedian 14.6x 14th
  • EV/EBITNegative EBIT −0.29xMedian 18.4x 11th
  • EV/RevenueRevenue is not positive −0.61xMedian 6.34x Not meaningful —
  • EV/FCFNegative free cash flow −0.71xMedian 23.4x 15th
  • EV/Operating cash flowNegative operating cash flow −0.71xMedian 19.3x 15th
  • PEG (3Y EPS CAGR)Implausibly low multiple 0.00Median 0.43 Not meaningful —
Peer group

Peer Comparison

Companies in the Biotechnology
View all peers
S.No. Ticker Company Market CapP/EP/STotal Debt (Qtr)
1 LLY ELI LILLY & Co 1,359.75 Bn46.7415.7349.50 Bn
2 JNJ Johnson & Johnson 688.76 Bn42.836.9344.65 Bn
3 ABBV AbbVie Inc. 521.69 Bn50.487.9080.90 Bn
4 MRK Merck & Co., Inc. 364.31 Bn148.685.4153.78 Bn
5 NVS Novartis Ag 306.35 Bn17.915.08-
6 AZN Astrazeneca Plc 285.96 Bn25.924.82-6.68 Bn
7 AMGN Amgen Inc 251.88 Bn26.836.4754.01 Bn
8 PTIX Protagenic Therapeutics, Inc.new 0.00 Bn0.15-0.67-